Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
4 lessons
10mSS-31 is elamipretide, a mitochondria-targeting peptide. FDA approved it in 2025 as Forzinity for one rare disease. Trials in other conditions mostly missed their main goals, and research vials are not the approved drug.
8mSS-31 and MOTS-c dominate mitochondrial peptide search. This list ranks the PeptIQ guides that answer dosage, timing, and stack questions without the forum noise.
8mSS-31 dosage searches keep climbing alongside MOTS-c. Here's the practical elamipretide dosing map — daily mg ranges, timing, cycling, and what to track for mitochondrial protocols.
8mSS-31 and MOTS-C target mitochondrial health from two different angles. Here's how to run them together, when to introduce each, and what to expect.
Also available at /blog for legacy links.